An unexpected and devastating adverse event of dasatinib: Rhabdomyolysis. (2016)

• Record Type: Journal Article
• Authors: Uz, Burak; Dolasik, Ilhan
• Is Part Of: Leukemia research reports. Volume 5(2016)
• Page Start: 1
• Page End: 2
• Publication Date: 2016
• Subjects: Dasatinib -- Rhabdomyolysis -- Creatine kinase; Leukemia -- Periodicals; Lymphomas -- Periodicals; Multiple myeloma -- Periodicals; Leukemia -- Periodicals; Lymphoma -- Periodicals; Multiple Myeloma -- Periodicals; Hematologic Neoplasms -- Periodicals; Leukemia; Lymphomas; Multiple myeloma; Electronic journals; Periodicals; 616.9941905
• DOI: 10.1016/j.lrr.2015.11.001
• Languages: English
• ISSNs: 2213-0489

Abstract

Abstract: We, herein, describe a 52-year-old male whom developed rhabdomyolysis and acute renal failure likely related to dasatinib shortly after the administration of treatment. After withdrawal of dasatinib, the myalgia reduced, and his CK returned to normal levels within a week. On follow-up acute renal failure did resolve without requiring dialysis, but unfortunately the patient died of severe respiratory distress. We recommend that musculoskeletal symptoms should be monitorized during therapy with dasatinib, and CML patients with musculoskeletal symptoms should have CK levels checked in order to prevent this unexpected but devastating adverse event. Highlights: Demonstration for the first time of rhabdomyolysis induced by dasatinib treatment. We recommend examining musculoskeletal symptoms and CML patients with musculoskeletal symptoms should have CK levels checked.